RMD · earnings call history
ResMed Q4 FY26 — Strong Growth, Strategic Portfolio Moves, and Increased Capital Returns
Read the briefResMed Inc. Q3 FY26 — Strong Revenue Growth, Margin Expansion, and Noctrix Acquisition
Read the briefResMed Q2 FY26 — Strong Revenue Growth, Margin Expansion, and Increased Share Repurchases
Read the briefResMed Q1 FY26 — Strong Revenue Growth and Gross Margin Expansion Driven by Devices and Masks
Read the briefResMed Q3 FY25 — Strong Growth, Margin Expansion, and Strategic Investments
Read the briefResMed Q2 FY25 — Strong Device and Mask Growth, Gross Margin Expansion
Read the briefBrowse all US companies on the earnings-call register.